Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera

Authors :: Kasopefoluwa Y. Oguntuyo
Christian S. Stevens
Chuan Tien Hung
Satoshi Ikegame
Joshua A. Acklin
Shreyas S. Kowdle
Jillian C. Carmichael
Hsin-Ping Chiu
Kristopher D. Azarm
Griffin D. Haas
Fatima Amanat
Jéromine Klingler
Ian Baine
Suzanne Arinsburg
Juan C. Bandres
Mohammed N. A. Siddiquey
Robert M. Schilke
Matthew D. Woolard
Hongbo Zhang
Andrew J. Duty
Thomas A. Kraus
Thomas M. Moran
Domenico Tortorella
Jean K. Lim
Andrea V. Gamarnik
Catarina E. Hioe
Susan Zolla-Pazner
Stanimir S. Ivanov
Jeremy P. Kamil
Florian Krammer
Benhur Lee
Source :: mBio, Vol 12, Iss 1 (2021)
Publication Year :: 2021
Publisher :: American Society for Microbiology, 2021.
Abstract: Vaccines and antibody-based therapeutics like convalescent-phase plasma therapy are premised upon inducing or transferring neutralizing antibodies that inhibit SARS-CoV-2 entry into cells. Virus neutralization assays (VNAs) for measuring neutralizing antibody titers (NATs) are an essential part of determining vaccine or therapeutic efficacy.

Full Text Access

Tools